

## **Semi-closed-circuit vacuum-assisted mini percutaneous nephrolithotomy in the pediatric population: the initial experience of two tertiary referral centers**

Journal: Minerva Urologica e Nefrologica

Paper code: Minerva Urol Nefrol-3951

Submission date: May 15, 2020

Article type: Original article

### Files:

1. Reply letter to comments on the manuscript  
Version: 1  
Description:  
File format: application/vnd.openxmlformats-officedocument.wordprocessingml.document
2. Manuscript  
Version: 2  
Description: Revised manuscript - Gallioli  
File format: application/vnd.openxmlformats-officedocument.wordprocessingml.document
3. Figures 1  
Version: 1  
Description: Figure 1 - Gallioli  
File format: image/tiff
4. Figures 2  
Version: 1  
Description: Figure 2 - Gallioli  
File format: image/tiff
5. Supplementary Digital Material 1  
Version: 1  
Description: Supplementary file - Gallioli  
File format: application/vnd.openxmlformats-officedocument.wordprocessingml.document

**REVISION NOTES**

Dear Editor,

please find enclosed the revised version of the manuscript entitled “Semi-closed-circuit vacuum-assisted mini percutaneous nephrolithotomy in pediatric patients” (Authors: Gallioli et al.; Minerva Urol Nefrol-3951) to be considered for publication in the Minerva Urologica & Nefrologica.

We are very grateful to the Reviewers and the Editors for their insightful comments to our paper.

Below, please find item-by-item responses to the comments, which are included verbatim. All pages and paragraph numbers refer to locations in the revised manuscript:

List of the changes made in the manuscript:

**Reviewer 1:**

Comments to the Author

In the current study, Gallioli et al. reported their initial experience on the use of a vacuum device for mini-PCNL in paediatric patients. The analysis was based on 18 mini-PCNLs performed in 13 children. Absence of stone fragments more than 4mm (stone free rate - SFR) and cost analysis were the primary outcomes of the study. Interesting 81.3% SFR was recorded in absence of peri and post-operative complications.

Overall, the manuscript sounds scientifically well.

However, it should be considered that the study is a case-series carried out in two high-volume urological hospitals. The nature of the study was the main limit as like authors have recognized too.

We are grateful to Reviewer 1 for the important and generally positive comments to our paper.

Major corrections:

1. As previously underlined, the study sample is underpower to analyse “safety and efficacy” as well it was not comparative. Thus, discussion sentences on “safety and efficacy should be replaced by “feasibility” idea.

**Answer 1:**

We agree with Reviewer 1 that the study is underpowered to analyze safety and efficacy of the vacuum device for mini-PCNL in the pediatric population. However, the study demonstrated that the device is safe, as no complications were reported during the procedures and the only postoperative major complication was represented by stent positioning for hydronephrosis and fever. Therefore, the concept of “safety and efficacy” was replaced by “safety and feasibility”.

Minor corrections:

2. postoperative CT has not been performed. That limit has been recognized in discussion, however underline that SFR may be overestimated due to absence of a more accurate imaging exam.

**Answer 2:**

We agree with the Reviewer 1. Therefore, a sentence underlining the risk of SFR overestimation was added in the Discussion section.

3. Then, have you considered to include experimental studies (if published) recording intra renal pressure by using ClearPetra system? This may improve your rationale based on mathematical count (Bernoulli’ principle) described in methods.

**Answer 3:**

We thank the Reviewer for this insightful comment. A study from Zanetti et al. (Vacuum-assisted mini-percutaneous nephrolithotomy: a new perspective in fragments clearance and intrarenal pressure

control. World J Urol. 2020;10.1007/s00345-020-03318-5. doi:10.1007/s00345-020-03318-5) has been added in the Methods section. The Authors demonstrate that using ClearPetra system the mean intrarenal pressure during 122 mini-PCNLs is 15 cmH<sub>2</sub>O (including pyelography, puncture, nephroscopy with closed aspiration) and that during lithotripsy the mean pressure was 13.29 cmH<sub>2</sub>O.

4. Clarify in methods and table 1 that you recorded the largest stone diameter (as underlined in line 35 page 9) as stone burden.

**Answer 4:**

We thank the Reviewer for this comment. We clarified that cumulative stone size was evaluated as as sum of largest stones diameter.

5. Have you considered to include HU in pre-operative stone findings? This may offer an idea of stone-hardness.

**Answer 5:**

We thank the Reviewer for this insightful comment. We could not provide the Hounsfield Units of all the stones as CT scan was not systematically performed. In order to reduce radiation exposure, ultrasound (US) and kidney-ureter-bladder x-ray were frequently employed.

**Reviewer 2:**

Comments to the Author

The joint effort has to be appreciated. The device is of interest but the results have to be critically interpreted and extensively discussed, while the final conclusions should be cautious, taking into serious account that we are talking of children (8-13 year-old).

We are grateful to Reviewer 2 for the important comments to our paper.

Major corrections:

1. A procedure in a child lasting 2 hours under general anesthesia, sometimes requiring 2 tracts, after about 50% of preoperative procedures like JJ, nephrostomy or both, with a 28% of postoperative fever (cut only 5.6% prep positive urine culture), a 39% of complications up to Clavien Dindo IIIa and the need for a further PNL or RIRS in 12% of cases is for sure feasible but not really miniinvasive as in the intentions of a miniaturized approach. Absence of blood transfusions is an issue but not the only one.

**Answer 1:**

We completely agree with Reviewer 2. The pediatric population that has been analyzed in the present study is generally complex, requiring a complex approach to treat the stones. The complications were mainly represented by fever (5/7 complications) which risk factors are represented by staghorn calculi (44% in our patients), low patient age and positive preoperative urine culture (Gutierrez J, Smith A, Geavlete P, et al. Urinary tract infections and post-operative fever in percutaneous nephrolithotomy. World J Urol. 2013;31(5):1135-1140. doi:10.1007/s00345-012-0836-y). So, our population had a high risk of infectious complications even if the preoperative urine culture was positive in only 5.6% patients. Moreover, the only high-grade complication was represented by stent DJ placement for hydronephrosis and fever. Therefore, we believe that the present treatment was as mini-invasive as possible in this specific population.

2. The choice of a rigid-only procedure of this kind with a number of technical limitations, especially in larger/staghorn stones (and often in metabolic young patients, should be extensively discussed. One should know why to choose this kind of procedure rather than a bit larger tract access with the possibility of quicker non-laser lithotripsy, better irrigation outflow, higher SFRs and may be lower complication rates.

**Answer 2:**

We thank Reviewer 2 for this important issue that needs to be clarified. The procedure was rigid but, in case of suspect of residual fragments, a flexible nephroscopy was performed.

The miniaturization of the technique may be particularly beneficial in the pediatric population, which in our case had a median age of 9 years and a median weight of 29 kg. It has been demonstrated that the renal injury following dilation is significantly wider when the tract is more than 22 French (Emiliani E, Talso M, Baghdadi M, Traxer O. Renal parenchyma injury after percutaneous nephrolithotomy tract dilatations in pig and cadaveric kidney models. Cent European J Urol. 2017;70(1):69-75. doi:10.5173/ceju.2017.930). A tract dilation of 16 French generates a renal fissure of a diameter of 4.4/6.28 mm in cadaveric/porcine model. On the other hand, a tract dilation of 24 French (standard-PCNL size) generates a renal fissure of 7.49/12.53 mm, almost doubling the diameter of a mini-PCNL and tripling the total dilation area. These findings explain why the tract dilation size is associated with hemorrhagic complications. The impact of a tract dilation on a pediatric kidney, which mean longest diameter is 9 cm in 10-year-old patients, is even more significant. Moreover, a staghorn stone may require more than one access, independently from the size of dilation, to reach and treat efficiently all the stones. For these reasons, we chose to perform mini-PCNL with 14 and 16 French access sheaths in these patients.

We acknowledge that the surgical time was generally long for the procedure. However, the total operative time did not reflect the total time spent in the renal cavity. Our surgical times might be affected by the first steps of the procedure as cystoscopy and ureteral catheterization (which might be challenging in Valdivia-Galdakao position) are performed by naive residents under the guidance of a tutor. We do not exceed 90 minutes of effective PCNL-surgery to reduce the risk of infectious complications. The irrigation outflow was guaranteed by the use of the ClearPetra system, which recently demonstrated to maintain mean intrarenal pressures of 15 cmH<sub>2</sub>O (11.03 mmHg) during mini-PCNL (Zanetti et al. Vacuum-assisted mini-percutaneous nephrolithotomy: a new perspective in fragments clearance and intrarenal pressure control. World J Urol. 2020;10.1007/s00345-020-03318-5. doi:10.1007/s00345-020-03318-5) and allows an optimal visualization of the intrarenal cavity. Finally, the stone-free rate and the complication rate were in line with current literature.

3. Costs should include prolonged hospitalizations for complications and ancillary procedures, not only of the single accessories! A honest discussion of such data is desirable, although the economic aspect is not a priority, compared to the pure clinical aspects.

**Answer 3:**

We agree with Reviewer 2. A complete cost analysis should also include complications and ancillary procedures. Considering that our study has no control group as reference, we could not compare complications and ancillary procedures to a standard procedure. The aim of our analysis of materials costs was to show the sustainability of the ClearPetra, which is disposable, in comparison to re-usable device that is currently employed in our Institutions (MIP Storz). Therefore, we changed the title of the dedicated paragraph, as the title "cost analysis" might be misleading.

Minor corrections:

4. Abstract, Methods: SFR was defined ... please specify with which kind of imaging (also lacking in the Materials and methods), to be added.

**Answer 4:**

The definition of stone-free rate and imaging performed during follow-up was added in Methods and Abstract.

5. Abstract, Results: the costs... please specify that costs do not include hospital stay but just instruments and devices.

**Answer 5:**

The sentence was corrected, specifying that the materials costs were only analyzed.

1  
2 6. Abstract, Results: what is standard mini-PNL for the authors in children? Please add.

3 **Answer 6:**

4 The sentence was corrected, and the term “standard mini-PCNL” was substituted by “mini-PCNL  
5 using a reusable set”.

6  
7 7. Throughout the text references are sometimes after the punctuation and not before. Please check  
8 according to the instructions of the authors, also for how to cite multiplmaginee references.

9 **Answer 7:**

10 The references in the text were completely checked and the errors in punctuation and citation style  
11 were corrected.

12  
13 8. 12F nephroscope, which one? size of the working channel? 9.5F semirigid ureteroscope, which  
14 one? size of the working channel. Please compare the irrigation outflow in two different devices like  
15 this. What about the length of the ureteroscope in a child and in percutaneous nephrolithotomy? please  
16 discuss.

17 **Answer 8:**

18 We used a 12 Fr nephroscope (Karl Storz SE & Co. KG, Germany; length: 22 cm; working channel  
19 6.7 Fr) for the 16 Fr ClearPetra, and a 9.5 Fr semirigid ureteroscope (Karl Storz SE & Co. KG,  
20 Germany; length: 34 cm; working channel 5 Fr) was used for the 14 Fr ClearPetra. The operators  
21 were used to 9.5 Fr semirigid ureteroscope in the setting of mini-PCNL, and felt comfortable with 34  
22 cm length (the shorter of the Storz ureteroscopes on the market).

23  
24 9. 1-5J x 10-20 Hz laser settings, please discuss the risk of heating within the collecting system with  
25 a 2 hours-procedure.

26 **Answer 9:**

27 We thank the Reviewer for this crucial comment. We corrected a typing error in the manuscript as  
28 our settings are 1-1.5J x 10-20 Hz.

29  
30 10. the kind of anesthesia is not reported, although imaginable.

31 **Answer 10:**

32 The type of anesthesia (general) was reported.

33  
34 Editorial revision:

35 Manuscript: The supplementary material has been quoted in the text.

36 Bibliography: the DOIs from the references were removed.

37  
38 We thank the Editor-in-Chief for the overall positive comment to our paper. The text has been revised  
39 accordingly.

40  
41 We hope that the paper is now suitable to be considered for publication in the Minerva Urologica &  
42 Nefrologica.

43 Sincerely yours,

44  
45 Andrea Gallioli on behalf of all the authors  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55

1 **Semi-closed-circuit vacuum-assisted mini percutaneous nephrolithotomy in the pediatric**  
2 **population: the initial experience of two tertiary referral centers**  
3  
4  
5  
6

7 Andrea Gallioli<sup>1\*</sup>, Alfredo Berrettini<sup>2</sup>, Gianluca Sampogna<sup>1,2</sup>, Erika Llorens<sup>3</sup>, Yesica Quiróz<sup>3</sup>,  
8 Michele Gnech<sup>2</sup>, Elisa De Lorenzis<sup>5</sup>, Giancarlo Albo<sup>5</sup>, Joan Palou<sup>4</sup>, Gianantonio Manzoni<sup>2</sup>, Anna  
9 Bujons<sup>3</sup>, Emanuele Montanari<sup>5</sup>  
10  
11

12  
13  
14 <sup>1</sup> Urology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, University of  
15 Milan, Milan, Italy

16  
17 <sup>2</sup> Pediatric Urology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan,  
18 Italy

19  
20 <sup>3</sup> Pediatric Urology Division, Fundació Puigvert, Barcelona, Spain

21  
22 <sup>4</sup> Urology Department, Fundació Puigvert, Barcelona, Spain

23  
24 <sup>5</sup> Urology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Department of  
25 Clinical Sciences and Community Health, University of Milan, Milan, Italy  
26

27  
28 \*Corresponding author: Andrea Gallioli, MD

29 Urology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico.

30 Via della Commenda 15.

31 Milan 20122, Italy.

32 Tel. +393496645072.

33 E-mail address: andrea.gallioli@gmail.com  
34  
35  
36  
37  
38  
39  
40

41 **Keywords:** percutaneous nephrolithotomy; urolithiasis; litholapaxy; children; kidney calculi  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55



## 1 ABSTRACT

### 2 3 4 **Background**

5 Percutaneous nephrolithotomy (PCNL) is the gold-standard for complex renal stones treatment in the  
6 pediatric population. While the miniaturization of PCNL reduces the risk of bleeding, it can hinder  
7 surgical and functional outcomes. The aim of the study is to assess the safety and feasibility of semi-  
8 closed-circuit vacuum-assisted Mini-PCNL (vmPCNL) in pediatric patients.  
9  
10  
11  
12

### 13 14 **Methods**

15 From January 2017 to December 2018, we prospectively collected data on consecutive vmPCNLs  
16 from two European tertiary referral centers. The procedure was performed with the ClearPetra®  
17 access sheath equipped with a lateral arm connected to the aspiration system (pressure setting ~ 120-  
18 150 cmH<sub>2</sub>O) by a 200 ml plastic stone collector. Pre-, intra- and post-operative data and costs were  
19 analyzed. The stone-free rate (SFR) was defined as absence of residual fragments > 4 mm with either  
20 ultrasound or kidney, ureter, and bladder x-ray.  
21  
22  
23  
24  
25  
26

### 27 **Results**

28 Eighteen vmPCNLs were performed in 16 renal units of 13 children. The median age was 119 months  
29 (IQR: 97-160) and the weight was 29 Kg (IQR: 25-40). The median cumulative stone size was 32  
30 mm (22-46) with 8 (44.4%) cases of staghorn stones. The OT was 128 min (IQR: 99-167). The  
31 basketing was unnecessary in 6/18 (33%) cases. Neither intra-operative complications nor blood  
32 transfusions occurred. Post-operative fever was observed in 5/18 (27.8%) cases; in one case a double  
33 J ureteral stent was placed for concomitant hydronephrosis. The SFR was 81.3% (13/16), rising to  
34 93.8% (15/16) after ancillary procedures. The materials costs of a vmPCNL (734.8 €) were  
35 comparable to mini-PCNL using a reusable set (710.7 €).  
36  
37  
38  
39  
40  
41  
42

### 43 **Conclusions**

44 The vmPCNL seems to be sustainable, safe and feasible for kidney stones treatment in the pediatric  
45 population.  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55

## INTRODUCTION

Surgical treatment of pediatric kidney stones has changed over the years [1]. Percutaneous nephrolithotomy (PCNL) was firstly introduced in 1976 and it still has a leading role despite many technological advancements in retrograde approaches [2-4]. According to the EAU guidelines, PCNL remains the first surgical option for renal stones > 20 mm (~300 mm<sup>2</sup>), for lower pole caliceal stones > 10 mm and for staghorn or multiple stones [5]. It ensures a higher stone-free rate (SFR) than shockwave lithotripsy (SWL) and retrograde intra-renal surgery (RIRS), despite presenting a higher rate of major complications and a higher decrease of post-operative hemoglobin levels [6].

In order to reduce PCNL morbidity, Jackman et al. introduced the Mini-PCNL in 1998, reporting encouraging results in terms of complication rate reduction. Their findings were subsequently confirmed by several randomized controlled trials (RCTs) [7]. Although mini-PCNL (nephrostomy tract size < 20 Fr) may reduce the number of major complications (haemorrhage in particular), some authors argue that it may decrease the SFR, lengthen the operative time (OT), and increase the number of post-operative urinary tract infections (UTI) [8,9].

Endourological research is currently focusing on regulating intra-renal pressures, especially, to reduce the risk of infection. During surgery, irrigation flow and irrigation pressures tend to be increased in order to achieve better visibility [10]. Increased intrarenal pressures can provoke the deterioration of the renal parenchyma, and cause pyelorenal backflow, fluid reabsorption, and bacteremia [11]. Novel systems to control and limit the increase of intra-renal pressures, like a semi-closed-circuit vacuum-assisted mini-PCNL (vmPCNL) system, may potentially reduce the number of post-operative complications and overcome some of the above-mentioned limitations of a minimally invasive approaches [12].

The aim of the study is to report our initial experience using a vmPCNL system for renal stone treatment and to assess its safety and efficacy in pediatric patients.

## MATERIALS AND METHODS

We prospectively collected data from two European tertiary referral centers: Fondazione IRCCS Ca' Granda - Ospedale Maggiore Policlinico (Milan) and Fundació Puigvert (Barcelona). From January 2017 to December 2018, we enrolled to the study all consecutive < 18 years old at the time of surgery undergoing a vmPCNL. Patients' data and surgical outcomes were retrospectively analyzed. The study was conducted in accordance with the Declaration of Helsinki (1964) and its later amendments. The study was approved by the Institutional Review Board. All patients signed an informed consent at the time of hospitalization to share anonymously clinical information for research purposes.



### *Data collection*

Pre-operative patient data included demographic variables (e.g. age, sex), medical history and stone characteristics, like **cumulative stone size (evaluated as sum of largest stones diameter)** and stone location, assessed by a non-contrast computed tomography (CT) scan or ultrasound (US) and kidney-ureter-bladder x-ray (KUB).

The analyzed intra-operative parameters were: OT, number of punctures required, intraoperative complications, and exit strategy.

The collected post-operative parameters were: length of hospital stay, post-operative complications (graded by the Clavien-Dindo classification), SFR, and the need for auxiliary procedures [13]. The stone-free status was assessed one month after surgery by means of two radiological exams, ultrasound (US) and kidney, ureter, and bladder (KUB) x-ray, and defined as the absence of residual fragments > 4 mm after one month from surgery.

### *Equipment and procedure*

Before starting the procedure, we administered antibiotic prophylaxis with a third-generation cephalosporin. In case of positive pre-operative urine culture, a targeted antibiotic therapy was scheduled prior to surgery on the basis of the urine culture antibiogram. **After general anaesthesia**, patients were positioned in Valdivia-Galdakao modified position. The first step was to gain ureteral access. It is our practice to use a 4.8 or 6 Fr open-ended ureteral catheter.

As for the nephrostomy access sheath, we used the ClearPetra® system (Well Lead Medical Co., Ltd., China), which is shown in Figure 1. This device is available in different measures: internal diameters range from 10 to 22 Fr and lengths can range from 13 to 21 cm. In Milan the 16-Fr x 13-cm access sheath was adopted, while in Barcelona surgeons preferred the 14-Fr x 13cm system.

A fluoroscopy-guided (+/- ultrasound) renal puncture was performed by the urologist. The tract was dilated in one-shot via the ClearPetra 16Fr access sheath. When the 14 Fr ClearPetra was used a progressive dilation by means of 8-10-12 Fr fascial dilators (Cook, Bloomington, IN, USA) was performed.

We used a 12 Fr nephroscope (**Karl Storz SE & Co. KG, Germany; length: 22 cm; working channel 6.7 Fr**) for the 16 Fr ClearPetra, and a 9.5 Fr semirigid ureteroscope (**Karl Storz SE & Co. KG, Germany; length: 34 cm; working channel 5 Fr**) was used for the 14 Fr ClearPetra.

The sheath is equipped with a lateral arm connected to the aspiration pipe which is linked to a 200 ml plastic bottle. The stone collection bottle has a valve that permits the aspiration of the fluids in the aspiration system without losing stone fragments. The aspiration strength can be adjusted in three ways. The first one is through a valve on the connecting tube. The second one is through an oval window on the lateral arm of the sheath that can be completely or partially closed by the connecting

1 tube. The third way is closing the oval window on-demand with a finger to temporarily increase the  
2 aspiration. The ClearPetra system is therefore characterized by a continuous inflow and a suction-  
3 controlled outflow.  
4

5 For estimation purposes, we considered our system as a closed one and estimated the involved  
6 variables. In accordance to Bernoulli's principle, the aspiration pressure should be  $p = -133 \text{ cmH}_2\text{O}$   
7 for the 16-Fr nephrostomy sheath/12-Fr nephroscope kit, and  $p = -143 \text{ cmH}_2\text{O}$  for the 14-Fr  
8 nephrostomy sheath/9.5-Fr ureteroscope kit (Figure 2; Appendix A). To allow a continuous flow of  
9 fluid with controlled intrarenal pressure of  $15 \text{ cmH}_2\text{O}$  as demonstrated by Zanetti et al. [14], the  
10 aspiration was set at  $\sim 120\text{-}150 \text{ cmH}_2\text{O}$ . Lithotripsy was performed with the Holmium:YAG laser  
11 (365-550  $\mu\text{m}$  fiber) with a frequency and energy setting of 10-20 Hz and 1-1.5 J, respectively.  
12 Litholapaxy was achieved by slowly drawing back the nephroscope inside the sheath until the opening  
13 of the lateral aspiration arm was reached. A red stripe on the sheath marks the limit for the  
14 nephroscope retraction. Baskets or forceps were not routinely used, except for stones located distant  
15 to the tip of the access sheath and/or located in difficult-to-reach positions (e.g. stones located in an  
16 upper calyx and renal access through a middle/lower calyx). Flexible nephroscopy was finally  
17 performed in case of doubt of residual fragments.  
18

19 The exit strategy varied according to the specificity of the scenario. A nephrostomy tube was usually  
20 left in place and removed after 24-48 hours. If the procedure was free from complications, and no  
21 large residual fragment was detected intraoperatively, the nephrostomy tube was not positioned.  
22 Instead, an indwelling ureteral catheter was kept in place for 1-2 days and subsequently removed.  
23 The bladder catheter was always left in place for at least 24-48 hours.  
24

### 25 *Analysis of materials costs*

26 All costs for standard materials and material specific of the procedure were analysed. The cost of the  
27 ClearPetra® system was compared to the cost of standard mini-PCNL (MIP set, Karl Storz SE & Co.  
28 KG, Germany), which was amortized on the average number of pediatric PCNL performed in the last  
29 two years.  
30

### 31 *Statistical analysis*

32 As for the statistical analysis, we estimated the median and interquartile range (IQR) for each  
33 quantitative variable, whereas for qualitative variables we reported the occurrence of the various  
34 outcomes. Data were stored and analyzed using Microsoft Excel (Microsoft Corporation,  
35 Washington, USA).  
36

## 37 **RESULTS**

1 Thirteen patients (8 males, 5 females) with a median age of 119 months (IQR: 97-160) and a median  
2 weight of 29 Kg (IQR: 25-40) were recruited for the study (Table 1). We performed 18 vmPCNLs in  
3 16 renal units - 10 right (55.6%) and 8 left (44.4%). Two patients had a pre-planned two-stage  
4 vmPCNL due to stone burden. In one additional case the decision to perform a second-look procedure  
5 was made intraoperatively due to the prolongation of the OT. Eight procedures (44.4%) were carried  
6 out on staghorn stones. Fifteen (83.3%) surgeries were performed for multiple renal stones. Six  
7 (33.3%) patients were pre-stented, 2 (11.1%) had a nephrostomy tube prior to the intervention and 2  
8 (11.1%) had both. The median cumulative stone size was 32 mm (IQR: 22-46) and was significantly  
9 higher in the population from Milan (37 mm vs 19 mm;  $p=0.02$ ). Seven out thirteen patients (53.8%)  
10 presented with comorbidities; among them some were predisposed to stone recurrence (e.g. primary  
11 hyperoxaluria type 1, cystinuria etc.). One patient had been submitted to a Cohen's ureterovesical  
12 reimplantation. No pre-operative blood test revealed anemia or a significant alteration of the renal  
13 function. One out of 18 cases presented with a positive pre-operative urine culture and underwent a  
14 7-day-long antibiotic therapy before performing vmPCNL.

#### 23 *Surgical procedure*

25 The median OT was 128 min (IQR: 99-167; Table 2). In 13 (72.2%) cases, a single tract dilation was  
26 performed; in 4 cases two tracts were necessary, whereas 3 tracts were only necessary in a single  
27 case. A lower-calyx dilation was used in 14 (58.3%) surgeries, while a first mid-calyx approach was  
28 preferred in 7 (29.2%) procedures. A dilation of the upper calyx was performed in 3 (12.5%)  
29 vmPCNLs. Stone removal was achieved only via suction in 6/18 (33%) of cases. At the end of the  
30 procedure, a nephrostomy tube was positioned in 83.3% (15/18) of cases. A double-J stent was  
31 positioned in 3 (16.7%) cases. All vmPCNLs were completed without intraoperative complications.

#### 36 *Outcomes*

38 Fever (5/18; 28%) was the most frequent post-operative complication. Two (11%) patients  
39 experienced a renal colic after nephrostomy closure or removal. Six (33.3%) patients presented a  
40 minor complication (Clavien-Dindo  $\leq$  II) during post-operative course. One (5.6%) patient underwent  
41 post-operative double-J ureteral stent positioning due to fever and hydronephrosis after catheter  
42 removal (Clavien-Dindo IIIa).

46 The stone composition was as follows: 3 calcium monohydrate oxalate, 3 calcium monohydrate  
47 oxalate and calcium carbonate, 2 cystine, and 5 phosphate-based infectious stones.

49 The median post-operative stay was 3 days (IQR: 3-6 days). No patient required blood transfusions.  
50 The SFR was confirmed in 13/16 renal units (81.3%). The SFR rised up to 93.8% (15/16) after  
51 ancillary procedures, such as second-look vmPCNL (n=1) or RIRS (n=2). The patient affected by  
52  
53  
54  
55

primary hyperoxaluria presenting with a bilateral urolithiasis, was subjected to one left-sided and two right-sided vmPCNLs. Stone-free status was only obtained in the right kidney.

#### **Analysis of materials costs**

The average cost of a mini-PCNL performed with vmPCNL or mini-PCNL using a reusable set was 734.8 € and 710.7 €, respectively (Table 3). The vmPCNL costed 24.1 € (+3,4%) more per surgery. The ClearPetra® system costed 256.2 € per surgery while standard mini-PCNL set 134.12 €. The standard materials costed 478.6 € for vmPCNL and 576.5 € for mini-PCNL using a reusable set, reflecting the less frequent use of the basket in vmPCNLs.

### **DISCUSSION**

In this study assessing the utility of vmPCNL in the pediatric population affected by complex stones, we demonstrated that this system was safe and feasible in the selected population.

Pediatric urolithiasis presents with different challenges from those encountered in the adults. In the pediatric age, stone formation is often associated with anatomical abnormalities, metabolic disorders, and UTIs, all factors that can increase recurrence risk [15,16]. Pediatric patients can be treated with minimally invasive techniques. However, children with large stone burdens, complete renal staghorn calculi, SWL-refractory stones, dilated or obstructed kidneys are best treated with PCNL.

In order to decrease the morbidity associated with PCNL, over the last few years miniaturized PCNL techniques have gained increased popularity [17]. The miniaturization of the technique may be particularly beneficial in the pediatric population. It has been demonstrated that the renal injury following dilation is significantly wider when the tract is more than 22 French. A tract dilation of 16 French generates a renal fissure of a diameter of 4.4/6.28 mm in cadaveric/porcine model. On the other hand, a tract dilation of 24 French (standard-PCNL size) generates a renal fissure of 7.49/12.53 mm, almost doubling the diameter of a mini-PCNL and tripling the total dilation area [18]. These findings explain why the tract dilation size is associated with hemorrhagic complications. The impact of a tract dilation on a pediatric kidney, which mean longest diameter is 9 cm in 10-year-old patients, is even more significant. However, their superiority in terms of safety and efficacy compared to conventional PCNL is still under debate.

The smaller tract size may be associated with decreased SFRs and, because of poor fluid drainage, elevated intra-renal pressures for a longer OT with respect to standard PCNL, increase the risk of infective complications [19,20].

In children with stones larger than 2 cm, Saad et al. showed that mini-PCNL has a higher SFR than RIRS (71% vs 95.5%, p=0.046), but it is nonetheless associated to higher radiation exposure, longer

1 hospital stay and more complications [21,22]. The rate of fever in the PCNL group was twice the one  
2  
3 of the RIRS group.

4 To improve the clinical outcomes related to mini-PCNL, research is currently focusing on avoiding  
5  
6 high intra-renal pressures [23]. vmPCNL system may control and limit intra-renal pressures above  
7  
8 the physiological limit of 30 mmHg, beside reducing the dissemination of stones in the pyelocaliceal  
9  
10 system during lithotripsy [12,14].

11 To the best of our knowledge, our study is the first to describe the use of a vmPCNL system in the  
12  
13 pediatric population. Our study demonstrated the **feasibility** of a vmPCNL approach in pediatric  
14  
15 patients. No intra-operative complications were recorded. During the post-operative period, no blood  
16  
17 transfusions were required, and 5 procedures were complicated by fever, with onset usually happened  
18  
19 on the first 24 hours.

20 Rashid et al. reported an initial SFR after Mini-PCNL for complex staghorn stones in children of  
21  
22 78%, which increased to 89% after a few ancillary procedures [24]. Their median OT was 91 min  
23  
24 (range 55–130 min). Our SFRs (81.3 and 93.8%) were comparable to the ones reported in the  
25  
26 literature. The SFR might be significantly conditioned by patients' predisposing factors to stone  
27  
28 formation (Table 1), which were present in 53.8% (7/13) of patients enrolled in our study. Moreover,  
29  
30 the stone burden was significant (median cumulative stone size = 32 mm). The vmPCNL seems a  
31  
32 sustainable procedure as total cost per procedure is slightly higher than a **mini-PCNL using a reusable**  
33  
34 **set**. Moreover, the average cost of a vmPCNL resembles the costs reported in literature for  
35  
36 percutaneous surgeries, ranging from 562.79 € to 749.39 € [25]. Our study presents several  
37  
38 limitations. To start with, the study design is associated with a low level of evidence, as it is not a  
39  
40 comparative study. The sample was relatively small. Both pre-operative stone burden and post-  
41  
42 operative status assessment were heterogeneous and not performed with the most accurate  
43  
44 radiological exams. Indeed, radiological assessment should be performed by CT imaging, as US has  
45  
46 a low sensitivity and inability to properly measure stone size [26]. This is in contrast with the pursuit  
47  
48 of limiting radiation exposure in children. Which is why we preferred to assess the SFR with US and  
49  
50 KUB x-rays limiting radiation exposure. **As a result, SFR might have been overestimated**. We  
51  
52 reported only the largest stone diameter instead of the entire stone volume [27]. The cumulated stone  
53  
54 size uses only one dimension, and this may limit its reliability, especially in case of complex stone  
55  
56 shape and stones > 20 mm [28,29].

57 According to our experience, the continuous aspiration was associated with a clear vision during the  
58  
59 procedure. Considering our high-risk population, the limited incidence of infectious complications in  
60  
61 our series may be associated with the low intra-renal pressures, warranted by the aspiration system.

1 Moreover, the facilitated litholapaxy and the absence of fragments scattering, guaranteed by the  
2 vmPCNL, may decrease OT and the need for disposable devices.  
3  
4

### 6 **CONCLUSIONS**

7 The use of a vmPCNL system seems to be a sustainable, safe and **feasible** procedure for kidney stones  
8 treatment in the pediatric population. Further multi-institutional RCTs are mandatory to test our initial  
9 hypothesis and to compare clinical outcomes of **mini-PCNL using a reusable set** versus vmPCNL.  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55

PEER REVIEW COPY  
Minerva Urologica e Nefrologica

### 54 **REFERENCES**



- 1 [1] Rassweiler J, Rassweiler MC, Klein J. New technology in ureteroscopy and percutaneous  
2 nephrolithotomy. *Current Opinion in Urology* 2016;26:95–106.
- 3 [2] Fernström I, Johansson B. Percutaneous pyelolithotomy. A new extraction technique. *Scand*  
4 *J Urol Nephrol* 1976;10:257–9.
- 5 [3] Sen H, Seckiner I, Bayrak O, Dogan K, Erturhan S. A comparison of micro-PERC and  
6 retrograde intrarenal surgery results in pediatric patients with renal stones. *Journal of Pediatric*  
7 *Urology* 2017;13:619.e1-619.e5.
- 8 [4] Ishii H, Griffin S, Somani BK. Flexible ureteroscopy and lasertripsy (FURSL) for paediatric  
9 renal calculi: Results from a systematic review. *Journal of Pediatric Urology* 2014;10:1020–5.
- 10 [5] EAU Guidelines. Edn. prese. Arnhem, The Netherlands: EAU Guidelines Office; 2019.
- 11 [6] De S, Autorino R, Kim FJ, Zargar H, Laydner H, Balsamo R, et al. Percutaneous  
12 nephrolithotomy versus retrograde intrarenal surgery: A systematic review and meta-analysis.  
13 *European Urology* 2015;67:125–37.
- 14 [7] Zanetti SP, Boeri L, Gallioli A, Talso M, Montanari E. Minimally invasive PCNL - MIP.  
15 *Archivos Espanoles de Urologia* 2017;70:226–34.
- 16 [8] Li LY, Gao X, Yang M, Li JF, Zhang H Bin, Xu WF, et al. Does a Smaller Tract in  
17 Percutaneous Nephrolithotomy Contribute to Less Invasiveness? A Prospective Comparative Study.  
18 *Urology* 2010;75:56–61.
- 19 [9] Zhu W, Liu Y, Liu L, Lei M, Yuan J, Wan SP, et al. Minimally invasive versus standard  
20 percutaneous nephrolithotomy: a meta-analysis. *Urolithiasis* 2015;43:563–70.
- 21 [10] Tokas T, Herrmann TRW, Skolarikos A, Nagele U. Pressure matters: intrarenal pressures  
22 during normal and pathological conditions, and impact of increased values to renal physiology.  
23 *World Journal of Urology* 2019;37:125–31.
- 24 [11] Tokas T, Skolarikos A, Herrmann TRW, Nagele U. Pressure matters 2: intrarenal pressure  
25 ranges during upper-tract endourological procedures. *World Journal of Urology* 2019;37:133–42.
- 26 [12] Zeng G, Wan S, Zhao Z, Zhu J, Fuerxun A, Song C, et al. Super-mini percutaneous  
27 nephrolithotomy (SMP): A new concept in technique and instrumentation. *BJU International*  
28 2016;117:655–61.
- 29 [13] Clavien PA, Barkun J, de Oliveira ML, Vauthey JN, Dindo D, Schulick RD, et al. The  
30 Clavien-Dindo Classification of Surgical Complications. *Annals of Surgery* 2009;250:187–96.
- 31 [14] Zanetti SP, Lievore E, Fontana M, Turetti M, Gallioli A, Longo F, et al. Vacuum-assisted  
32 mini-percutaneous nephrolithotomy: a new perspective in fragments clearance and intrarenal  
33 pressure control. *World J Urol* 2020.
- 34 [15] Bujons A, Millán F, Centeno C, Emiliani E, Sánchez Martín F, Angerri O, et al. Mini-  
35 percutaneous nephrolithotomy with high-power holmium YAG laser in pediatric patients with  
36 staghorn and complex calculi. *Journal of Pediatric Urology* 2016;12:253.e1-253.e5.
- 37 [16] Berrettini A, Boeri L, Montanari E, Mogiatti M, Acquati P, De Lorenzis E, et al. Retrograde  
38 intrarenal surgery using ureteral access sheaths is a safe and effective treatment for renal stones in  
39 children weighing <20 kg. *Journal of Pediatric Urology* 2018;14:59.e1-59.e6.
- 40 [17] Zeng G, Zhu W, Lam W. Miniaturised percutaneous nephrolithotomy: Its role in the  
41 treatment of urolithiasis and our experience. *Asian Journal of Urology* 2018;5:295–302.
- 42 [18] Emiliani E, Talso M, Baghdadi M, Traxer O. Renal parenchyma injury after percutaneous  
43 nephrolithotomy tract dilatations in pig and cadaveric kidney models. *Cent European J Urol*  
44 2017;70:69–75. <https://doi.org/10.5173/cej.2017.930>.
- 45 [19] Kaygısız O, Satar N, Gürocak S, Kefi A, İzol V, Önal B, et al. Factors predicting  
46 postoperative febrile urinary tract infection following percutaneous nephrolithotomy in prepubertal  
47 children. *Journal of Pediatric Urology* 2018;14:448.e1-448.e7.
- 48 [20] Loftus CJ, Hinck B, Makovey I, Sivalingam S, Monga M. Mini Versus Standard  
49 Percutaneous Nephrolithotomy: The Impact of Sheath Size on Intrarenal Pelvic Pressure and  
50 Infectious Complications in a Porcine Model. *Journal of Endourology* 2018;32:350–3.
- 51 [21] Saad KSM, Youssif ME, Hamdy SAIN, Fahmy A, El Din Hanno AG, El-Nahas AR.
- 52
- 53
- 54
- 55

1 Percutaneous nephrolithotomy vs retrograde intrarenal surgery for large renal stones in pediatric  
 2 patients: A randomized controlled trial. *Journal of Urology* 2015;194:1716–20.

3 [22] Lu P, Song R, Yu Y, Yang J, Qi K, Tao R, et al. Clinical efficacy of percutaneous  
 4 nephrolithotomy versus retrograde intrarenal surgery for pediatric kidney urolithiasis. *Medicine*  
 5 (United States) 2017;96.

6 [23] Walcher U, Horstmann M, Anastasiadis AG, Nagele U, Hennenlotter J, Sievert K-D, et al. A  
 7 Newly Designed Amplatz Sheath Decreases Intrapelvic Irrigation Pressure During Mini-  
 8 Percutaneous Nephrolitholapaxy: An in-Vitro Pressure-Measurement and Microscopic Study .  
 9 *Journal of Endourology* 2007;21:1113–6.

10 [24] Rashid AO, Amin SH, Al Kadum MA, Mohammed SK, Buchholz N. Mini-Percutaneous  
 11 Nephrolithotomy for Complex Staghorn Stones in Children. *Urologia Internationalis* 2019;1–4.

12 [25] Schoenthaler M, Wilhelm K, Hein S, Adams F, Schlager D, Wetterauer U, et al. Ultra-mini  
 13 PCNL versus flexible ureteroscopy: a matched analysis of treatment costs (endoscopes and  
 14 disposables) in patients with renal stones 10-20 mm. *World J Urol* 2015;33:1601–5.

15 [26] Ganesan V, De S, Greene D, Torricelli FCM, Monga M. Accuracy of ultrasonography for  
 16 renal stone detection and size determination: is it good enough for management decisions? *BJU*  
 17 *International* 2017;119:464–9.

18 [27] De Coninck V, Traxer O. The Time Has Come to Report Stone Burden in Terms of Volume  
 19 Instead of Largest Diameter. *Journal of Endourology* 2018;32:265–6.

20 [28] Ito H, Kawahara T, Terao H, Ogawa T, Yao M, Kubota Y, et al. Utility and limitation of  
 21 cumulative stone diameter in predicting urinary stone burden at flexible ureteroscopy with holmium  
 22 laser lithotripsy: a single-center experience. *PLoS ONE* 2013;8:e65060.

23 [29] Giusti G, Proietti S, Villa L, Cloutier J, Rosso M, Gadda GM, et al. Current Standard  
 24 Technique for Modern Flexible Ureteroscopy: Tips and Tricks. *Eur Urol* 2016;70:188–94.

25  
 26  
 27  
 28 **Conflicts of interest:** The Authors declare nothing to disclose.

29  
 30  
 31 **Authors' contributions:**

32 Study design: Berrettini A, Bujons A, Manzoni G, Montanari E

33 Data collection: Gallioli A, Sampogna G, Quiróz Y, Llorens E

34 Manuscript writing: Gallioli A, Sampogna G, Gnech M, De Lorenzis E

35 Manuscript editing: Bujons A, Montanari E, Palou J, Albo G

36  
 37  
 38  
 39  
 40  
 41 **Funding:** none

42  
 43 **Acknowledgements:** Carolina Bebi for language revision and Irene Fulgheri for cost analysis.  
 44  
 45  
 46  
 47  
 48  
 49  
 50  
 51  
 52  
 53  
 54  
 55

## TABLES

**Table 1.** Baseline characteristics of the population

Parameters	Values
<b>No. patients</b>	13 - 8 Milan (61.5%) - 5 Barcelona (38.5%)
<b>No. renal units</b>	16
<b>No. vmPCNLs</b>	18
<b>Sex</b>	- Males: 8 (61.5%) - Females: 5 (38.5%)
<b>Age (months) median (IQR)</b>	119 (97-160)
<b>Weight (Kg) median (IQR)</b>	29 (25-40)
<b>BMI (Kg/m<sup>2</sup>) median (IQR)</b>	17.7 (16.4-18.3)
<b>Type of stone</b>	- Staghorn: 8 (44.4%) - Multiple: 15 (83.3%)
<b>Stone side</b>	- Right: 10 (55.6%) - Left: 8 (44.4%)
<b>Cumulative stone size (mm)* median (IQR)</b>	32 (22-46)
<b>No. patients with comorbidities</b>	7 (53.8%) - Primary hyperoxaluria type 1 (7.7%) - Cystinuria: 2 (15.4%) - Bladder exstrophy: 1 (7.7%) - Distal renal tubular acidosis: 1 (7.7%) - Bilateral ureteral reimplantation according to Cohen: 1 (7.7%) - Kabuki syndrome: 1 (7.7%) - Posterior urethral valves: 1 (7.7%) - Gastroschisis: 1 (7.7%)
<b>Pre-operative condition</b>	- Ureteral DJ stent: 6 (33.3%) - Nephrostomy tube: 2 (11.1%) - Ureteral DJ stent + nephrostomy tube: 2 (11.1%)
<b>Pre-operative hemoglobin (g/dL) median (IQR)</b>	13.2 (12.1-13.7)
<b>Pre-operative creatinine (mg/dL) median (IQR)</b>	0.7 (0.5-1.1)
<b>Pre-operative sodium (mEq/dL) median (IQR)</b>	140 (138-142)
<b>Pre-operative potassium (mEq/dL) median (IQR)</b>	4.6 (4.3-4.7)
<b>Pre-operative calcium (mg/dL) median (IQR)</b>	9.8 (9.6-9.9)
<b>Pre-operative uric acid (mg/dL) median (IQR)</b>	3.9 (3.4-4.2)
<b>Positive pre-operative urine culture (%)</b>	5.6 (1/18) - Pseudomonas aeruginosa

\* Cumulative stone size was evaluated as sum of largest stones diameter

BMI = body mass index; IQR = inter-quartile range; vmPCNL = semi-closed-circuit vacuum-assisted Mini-PCNL.

**Table 2.** Intra- and post-operative data of the patients submitted to vmPCNL

Parameters	Values
<b>Operative time (min) median (IQR)</b>	128 (99-167)
<b>Tract location</b>	Upper calyx: 3 (12.5) Middle calyx: 7 (29.2) Lower calyx: 14 (58.3)
<b>Tract</b>	Single: 13 (72.2) Multiple: 5 (27.8)
<b>Intra-operative complications (%)</b>	0
<b>Exit strategy</b>	- Nephrostomy tube: 15 (83.3%) [in one case: two nephrostomy tubes] - Tubeless: 3 (16.7%) - double-J ureteral stent: 3 (16.7%) - single-J ureteral catheter: 5 (27.8%)
<b>Stone composition</b>	- Calcium oxalate monohydrate: 3 (23.1%) - Calcium oxalate monohydrate and calcium carbonate: 3 (23.1%) - Cystine: 2 (15.4%) - Phosphate-based infectious stones (e.g. struvite, carboapatite): 5 (38.5%)
<b>Fever (%)</b>	27.8 (5/18)
<b>Blood transfusion (%)</b>	0
<b>Complications according to Clavien-Dindo classification (%)</b>	
- Grade I-II	- 33.3 (6/18)
- Grade IIIa	- 5.6 (1/18)
<b>Hospital stay (days) median (IQR)</b>	3 (3-6)
<b>Post-operative hemoglobin (g/dL) median (IQR)*</b>	12.1 (11.3-13.2)
<b>Post-operative creatinine (mg/dL) median (IQR)**</b>	0.61 (0.52-0.86)
<b>Post-operative CRP (mg/L) median (IQR)**</b>	3.3 (1.8-4.8)
<b>Stone-free rate (%)</b>	81.3 (13/16)
<b>Stone-free rate after ancillary procedures (%)</b>	93.8 (15/16)

vmPCNL = semi-closed-circuit vacuum-assisted Mini-PCNL; CRP = C-reactive protein; IQR = inter-quartile range

**Table 3.** Analysis of the disposable and reusable materials cost for mini-PCNL, stratified for mini-PCNL using a reusable set (standard) and vacuum-assisted mini-PCNL (excluding endoscopes)

Materials	Quantity	Price (€)	Standard mini-PCNL (€)	Vacuum-assisted mini-PCNL (€)
Ureteral catheter	1	10.0	10.0	10.0
Hydrophilic wire	2	24.3	48.6	48.6
Basket	1	146.2	146.2	48.3
Laser fiber*	1	888.2	88.8	88.8
Nephrostomy set	1	73.2	73.2	73.2
Irrigation set**	1	136.1	78.4	78.4
Contrast	1	29.3	29.3	29.3
Lubrication	2	1.9	3.8	3.8
Gowns/gloves	5	2.5	12.7	12.7
Draping	1	62.0	62.0	62.0
Miscellaneous	/	23.6	23.6	23.6
PCNL set***	1	1475.3	134.1	/
ClearPetra	1	256.2	/	256.2
<b>Total</b>	/	/	710.7	734.8

\* Depreciation calculated on 10 procedures

\*\* Depreciation calculated on 4 procedures

\*\*\* Depreciation calculated on the number of pediatric PCNLs performed in the last 24 months

## TITLES OF FIGURES

1  
2  
3 **Figure 1.** A) The ClearPetra® system (Well Lead Medical Co., Ltd., China), is shown. A plug is put  
4 over the external access to prevent the medium from flowing out. The sheath is equipped with a lateral  
5 arm connected to the aspiration system through a 200 ml plastic bottle, which collects stone  
6 fragments. B) The pressure vent on the lateral arm is used to regulate aspiration and the red stripe on  
7 the sheath is the mark for endoscope retraction. D) Lapaxy is performed by slowly drawing back the  
8 nephroscope inside the sheath until the red stripe on the sheath, thus aspirating the fragments in the  
9 lateral arm.  
10  
11  
12  
13  
14  
15  
16  
17  
18

19 **Figure 2.** Estimation of the pressures involved in the employed system. The entire circuit was  
20 considered as closed for estimation purposes. Bernoulli's principle states the total pressure is a  
21 constant in the system and derives from the sum of static and dynamic pressures. In the example  
22 shown, we considered the 16-Fr nephrostomy sheath and 12-Fr nephroscope, evaluating the aspiration  
23 pressure in  $p = -13.013Pa = -133 \text{ cmH}_2\text{O}$ . To estimate the pressure with a 9.5-Fr ureteroscope and a  
24 14-Fr nephrostomy sheath, the values of  $r_1$  and  $r_2$  were modified accordingly, obtaining a final  
25 aspiration pressure  $p = -14.00Pa = -143 \text{ cmH}_2\text{O}$ .  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55



1 **Semi-closed-circuit vacuum-assisted mini percutaneous nephrolithotomy in the pediatric**  
2 **population: the initial experience of two tertiary referral centers**  
3  
4

5  
6  
7 Andrea Gallioli<sup>1\*</sup>, Alfredo Berrettini<sup>2</sup>, Gianluca Sampogna<sup>1,2</sup>, Erika Llorens<sup>3</sup>, Yesica Quiróz<sup>3</sup>,  
8 Michele Gnech<sup>2</sup>, Elisa De Lorenzis<sup>5</sup>, Giancarlo Albo<sup>5</sup>, Joan Palou<sup>4</sup>, Gianantonio Manzoni<sup>2</sup>, Anna  
9 Bujons<sup>3</sup>, Emanuele Montanari<sup>5</sup>  
10  
11

12  
13  
14 <sup>1</sup> Urology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, University of  
15 Milan, Milan, Italy  
16

17 <sup>2</sup> Pediatric Urology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan,  
18 Italy  
19

20 <sup>3</sup> Pediatric Urology Division, Fundació Puigvert, Barcelona, Spain  
21

22 <sup>4</sup> Urology Department, Fundació Puigvert, Barcelona, Spain  
23

24 <sup>5</sup> Urology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Department of  
25 Clinical Sciences and Community Health, University of Milan, Milan, Italy  
26

27  
28 \*Corresponding author: Andrea Gallioli, MD  
29

30 Urology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico.  
31

32 Via della Commenda 15.  
33

34 Milan 20122, Italy.  
35

36 Tel. +393496645072.  
37

38 E-mail address: andrea.gallioli@gmail.com  
39  
40

41 **Keywords:** percutaneous nephrolithotomy; urolithiasis; litholapaxy; children; kidney calculi  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55

## 1 ABSTRACT

### 2 3 4 **Background**

5 Percutaneous nephrolithotomy (PCNL) is the gold-standard for complex renal stones treatment in the  
6 pediatric population. While the miniaturization of PCNL reduces the risk of bleeding, it can hinder  
7 surgical and functional outcomes. The aim of the study is to assess the safety and feasibility of semi-  
8 closed-circuit vacuum-assisted Mini-PCNL (vmPCNL) in pediatric patients.  
9  
10  
11

### 12 13 14 **Methods**

15 From January 2017 to December 2018, we prospectively collected data on consecutive vmPCNLs  
16 from two European tertiary referral centers. The procedure was performed with the ClearPetra®  
17 access sheath equipped with a lateral arm connected to the aspiration system (pressure setting ~ 120-  
18 150 cmH<sub>2</sub>O) by a 200 ml plastic stone collector. Pre-, intra- and post-operative data and costs were  
19 analyzed. The stone-free rate (SFR) was defined as absence of residual fragments > 4 mm with either  
20 ultrasound or kidney, ureter, and bladder x-ray.  
21  
22  
23  
24

### 25 26 27 **Results**

28 Eighteen vmPCNLs were performed in 16 renal units of 13 children. The median age was 119 months  
29 (IQR: 97-160) and the weight was 29 Kg (IQR: 25-40). The median cumulative stone size was 32  
30 mm (22-46) with 8 (44.4%) cases of staghorn stones. The OT was 128 min (IQR: 99-167). The  
31 basketing was unnecessary in 6/18 (33%) cases. Neither intra-operative complications nor blood  
32 transfusions occurred. Post-operative fever was observed in 5/18 (27.8%) cases; in one case a double  
33 J ureteral stent was placed for concomitant hydronephrosis. The SFR was 81.3% (13/16), rising to  
34 93.8% (15/16) after ancillary procedures. The materials costs of a vmPCNL (734.8 €) were  
35 comparable to mini-PCNL using a reusable set (710.7 €).  
36  
37  
38  
39  
40  
41  
42

### 43 **Conclusions**

44 The vmPCNL seems to be sustainable, safe and feasible for kidney stones treatment in the pediatric  
45 population.  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55

## INTRODUCTION

Surgical treatment of pediatric kidney stones has changed over the years [1]. Percutaneous nephrolithotomy (PCNL) was firstly introduced in 1976 and it still has a leading role despite many technological advancements in retrograde approaches [2-4]. According to the EAU guidelines, PCNL remains the first surgical option for renal stones > 20 mm (~300 mm<sup>2</sup>), for lower pole caliceal stones > 10 mm and for staghorn or multiple stones [5]. It ensures a higher stone-free rate (SFR) than shockwave lithotripsy (SWL) and retrograde intra-renal surgery (RIRS), despite presenting a higher rate of major complications and a higher decrease of post-operative hemoglobin levels [6].

In order to reduce PCNL morbidity, Jackman et al. introduced the Mini-PCNL in 1998, reporting encouraging results in terms of complication rate reduction. Their findings were subsequently confirmed by several randomized controlled trials (RCTs) [7]. Although mini-PCNL (nephrostomy tract size < 20 Fr) may reduce the number of major complications (haemorrhage in particular), some authors argue that it may decrease the SFR, lengthen the operative time (OT), and increase the number of post-operative urinary tract infections (UTI) [8,9].

Endourological research is currently focusing on regulating intra-renal pressures, especially, to reduce the risk of infection. During surgery, irrigation flow and irrigation pressures tend to be increased in order to achieve better visibility [10]. Increased intrarenal pressures can provoke the deterioration of the renal parenchyma, and cause pyelorenal backflow, fluid reabsorption, and bacteremia [11]. Novel systems to control and limit the increase of intra-renal pressures, like a semi-closed-circuit vacuum-assisted mini-PCNL (vmPCNL) system, may potentially reduce the number of post-operative complications and overcome some of the above-mentioned limitations of a minimally invasive approaches [12].

The aim of the study is to report our initial experience using a vmPCNL system for renal stone treatment and to assess its safety and efficacy in pediatric patients.

## MATERIALS AND METHODS

We prospectively collected data from two European tertiary referral centers: Fondazione IRCCS Ca' Granda - Ospedale Maggiore Policlinico (Milan) and Fundació Puigvert (Barcelona). From January 2017 to December 2018, we enrolled to the study all consecutive < 18 years old at the time of surgery undergoing a vmPCNL. Patients' data and surgical outcomes were retrospectively analyzed. The study was conducted in accordance with the Declaration of Helsinki (1964) and its later amendments. The study was approved by the Institutional Review Board. All patients signed an informed consent at the time of hospitalization to share anonymously clinical information for research purposes.

### *Data collection*

Pre-operative patient data included demographic variables (e.g. age, sex), medical history and stone characteristics, like cumulative stone size (evaluated as sum of largest stones diameter) and stone location, assessed by a non-contrast computed tomography (CT) scan or ultrasound (US) and kidney-ureter-bladder x-ray (KUB).

The analyzed intra-operative parameters were: OT, number of punctures required, intraoperative complications, and exit strategy.

The collected post-operative parameters were: length of hospital stay, post-operative complications (graded by the Clavien-Dindo classification), SFR, and the need for auxiliary procedures [13]. The stone-free status was assessed one month after surgery by means of two radiological exams, ultrasound (US) and kidney, ureter, and bladder (KUB) x-ray, and defined as the absence of residual fragments > 4 mm after one month from surgery.

### *Equipment and procedure*

Before starting the procedure, we administered antibiotic prophylaxis with a third-generation cephalosporin. In case of positive pre-operative urine culture, a targeted antibiotic therapy was scheduled prior to surgery on the basis of the urine culture antibiogram. After general anaesthesia, patients were positioned in Valdivia-Galdakao modified position. The first step was to gain ureteral access. It is our practice to use a 4.8 or 6 Fr open-ended ureteral catheter.

As for the nephrostomy access sheath, we used the ClearPetra® system (Well Lead Medical Co., Ltd., China), which is shown in Figure 1. This device is available in different measures: internal diameters range from 10 to 22 Fr and lengths can range from 13 to 21 cm. In Milan the 16-Fr x 13-cm access sheath was adopted, while in Barcelona surgeons preferred the 14-Fr x 13cm system.

A fluoroscopy-guided (+/- ultrasound) renal puncture was performed by the urologist. The tract was dilated in one-shot via the ClearPetra 16Fr access sheath. When the 14 Fr ClearPetra was used a progressive dilation by means of 8-10-12 Fr fascial dilators (Cook, Bloomington, IN, USA) was performed.

We used a 12 Fr nephroscope (Karl Storz SE & Co. KG, Germany; length: 22 cm; working channel 6.7 Fr) for the 16 Fr ClearPetra, and a 9.5 Fr semirigid ureteroscope (Karl Storz SE & Co. KG, Germany; length: 34 cm; working channel 5 Fr) was used for the 14 Fr ClearPetra.

The sheath is equipped with a lateral arm connected to the aspiration pipe which is linked to a 200 ml plastic bottle. The stone collection bottle has a valve that permits the aspiration of the fluids in the aspiration system without losing stone fragments. The aspiration strength can be adjusted in three ways. The first one is through a valve on the connecting tube. The second one is through an oval window on the lateral arm of the sheath that can be completely or partially closed by the connecting

1 tube. The third way is closing the oval window on-demand with a finger to temporarily increase the  
2 aspiration. The ClearPetra system is therefore characterized by a continuous inflow and a suction-  
3 controlled outflow.  
4

5 For estimation purposes, we considered our system as a closed one and estimated the involved  
6 variables. In accordance to Bernoulli's principle, the aspiration pressure should be  $p = -133 \text{ cmH}_2\text{O}$   
7 for the 16-Fr nephrostomy sheath/12-Fr nephroscope kit, and  $p = -143 \text{ cmH}_2\text{O}$  for the 14-Fr  
8 nephrostomy sheath/9.5-Fr ureteroscope kit (Figure 2; Appendix A). To allow a continuous flow of  
9 fluid with controlled intrarenal pressure of 15 cmH<sub>2</sub>O as demonstrated by Zanetti et al. [14], the  
10 aspiration was set at ~ 120-150 cmH<sub>2</sub>O. Lithotripsy was performed with the Holmium:YAG laser  
11 (365-550 μm fiber) with a frequency and energy setting of 10-20 Hz and 1-1.5 J, respectively.  
12 Litholapaxy was achieved by slowly drawing back the nephroscope inside the sheath until the opening  
13 of the lateral aspiration arm was reached. A red stripe on the sheath marks the limit for the  
14 nephroscope retraction. Baskets or forceps were not routinely used, except for stones located distant  
15 to the tip of the access sheath and/or located in difficult-to-reach positions (e.g. stones located in an  
16 upper calyx and renal access through a middle/lower calyx). Flexible nephroscopy was finally  
17 performed in case of doubt of residual fragments.

18 The exit strategy varied according to the specificity of the scenario. A nephrostomy tube was usually  
19 left in place and removed after 24-48 hours. If the procedure was free from complications, and no  
20 large residual fragment was detected intraoperatively, the nephrostomy tube was not positioned.  
21 Instead, an indwelling ureteral catheter was kept in place for 1–2 days and subsequently removed.  
22 The bladder catheter was always left in place for at least 24-48 hours.

### 23 *Analysis of materials costs*

24 All costs for standard materials and material specific of the procedure were analysed. The cost of the  
25 ClearPetra® system was compared to the cost of standard mini-PCNL (MIP set, Karl Storz SE & Co.  
26 KG, Germany), which was amortized on the average number of pediatric PCNL performed in the last  
27 two years.

### 28 *Statistical analysis*

29 As for the statistical analysis, we estimated the median and interquartile range (IQR) for each  
30 quantitative variable, whereas for qualitative variables we reported the occurrence of the various  
31 outcomes. Data were stored and analyzed using Microsoft Excel (Microsoft Corporation,  
32 Washington, USA).

## 33 **RESULTS**

1 Thirteen patients (8 males, 5 females) with a median age of 119 months (IQR: 97-160) and a median  
2 weight of 29 Kg (IQR: 25-40) were recruited for the study (Table 1). We performed 18 vmPCNLs in  
3 16 renal units - 10 right (55.6%) and 8 left (44.4%). Two patients had a pre-planned two-stage  
4 vmPCNL due to stone burden. In one additional case the decision to perform a second-look procedure  
5 was made intraoperatively due to the prolongation of the OT. Eight procedures (44.4%) were carried  
6 out on staghorn stones. Fifteen (83.3%) surgeries were performed for multiple renal stones. Six  
7 (33.3%) patients were pre-stented, 2 (11.1%) had a nephrostomy tube prior to the intervention and 2  
8 (11.1%) had both. The median cumulative stone size was 32 mm (IQR: 22-46) and was significantly  
9 higher in the population from Milan (37 mm vs 19 mm;  $p=0.02$ ). Seven out thirteen patients (53.8%)  
10 presented with comorbidities; among them some were predisposed to stone recurrence (e.g. primary  
11 hyperoxaluria type 1, cystinuria etc.). One patient had been submitted to a Cohen's ureterovesical  
12 reimplantation. No pre-operative blood test revealed anemia or a significant alteration of the renal  
13 function. One out of 18 cases presented with a positive pre-operative urine culture and underwent a  
14 7-day-long antibiotic therapy before performing vmPCNL.

#### 23 *Surgical procedure*

25 The median OT was 128 min (IQR: 99-167; Table 2). In 13 (72.2%) cases, a single tract dilation was  
26 performed; in 4 cases two tracts were necessary, whereas 3 tracts were only necessary in a single  
27 case. A lower-calyx dilation was used in 14 (58.3%) surgeries, while a first mid-calyx approach was  
28 preferred in 7 (29.2%) procedures. A dilation of the upper calyx was performed in 3 (12.5%)  
29 vmPCNLs. Stone removal was achieved only via suction in 6/18 (33%) of cases. At the end of the  
30 procedure, a nephrostomy tube was positioned in 83.3% (15/18) of cases. A double-J stent was  
31 positioned in 3 (16.7%) cases. All vmPCNLs were completed without intraoperative complications.

#### 36 *Outcomes*

38 Fever (5/18; 28%) was the most frequent post-operative complication. Two (11%) patients  
39 experienced a renal colic after nephrostomy closure or removal. Six (33.3%) patients presented a  
40 minor complication (Clavien-Dindo  $\leq$  II) during post-operative course. One (5.6%) patient underwent  
41 post-operative double-J ureteral stent positioning due to fever and hydronephrosis after catheter  
42 removal (Clavien-Dindo IIIa).

46 The stone composition was as follows: 3 calcium monohydrate oxalate, 3 calcium monohydrate  
47 oxalate and calcium carbonate, 2 cystine, and 5 phosphate-based infectious stones.

49 The median post-operative stay was 3 days (IQR: 3-6 days). No patient required blood transfusions.  
50 The SFR was confirmed in 13/16 renal units (81.3%). The SFR rised up to 93.8% (15/16) after  
51 ancillary procedures, such as second-look vmPCNL (n=1) or RIRS (n=2). The patient affected by  
52  
53  
54  
55



1 primary hyperoxaluria presenting with a bilateral urolithiasis, was subjected to one left-sided and two  
2 right-sided vmPCNLs. Stone-free status was only obtained in the right kidney.

#### 4 *Analysis of materials costs*

5 The average cost of a mini-PCNL performed with vmPCNL or mini-PCNL using a reusable set was  
6 734.8 € and 710.7 €, respectively (Table 3). The vmPCNL costed 24.1 € (+3,4%) more per surgery.  
7 The ClearPetra® system costed 256.2 € per surgery while standard mini-PCNL set 134.12 €. The  
8 standard materials costed 478.6 € for vmPCNL and 576.5 € for mini-PCNL using a reusable set,  
9 reflecting the less frequent use of the basket in vmPCNLs.  
10  
11  
12  
13  
14

## 15 **DISCUSSION**

16 In this study assessing the utility of vmPCNL in the pediatric population affected by complex stones,  
17 we demonstrated that this system was safe and feasible in the selected population.  
18

19 Pediatric urolithiasis presents with different challenges from those encountered in the adults. In the  
20 pediatric age, stone formation is often associated with anatomical abnormalities, metabolic disorders,  
21 and UTIs, all factors that can increase recurrence risk [15,16]. Pediatric patients can be treated with  
22 minimally invasive techniques. However, children with large stone burdens, complete renal staghorn  
23 calculi, SWL-refractory stones, dilated or obstructed kidneys are best treated with PCNL.  
24  
25  
26  
27

28 In order to decrease the morbidity associated with PCNL, over the last few years miniaturized PCNL  
29 techniques have gained increased popularity [17]. The miniaturization of the technique may be  
30 particularly beneficial in the pediatric population. It has been demonstrated that the renal injury  
31 following dilation is significantly wider when the tract is more than 22 French. A tract dilation of 16  
32 French generates a renal fissure of a diameter of 4.4/6.28 mm in cadaveric/porcine model. On the  
33 other hand, a tract dilation of 24 French (standard-PCNL size) generates a renal fissure of 7.49/12.53  
34 mm, almost doubling the diameter of a mini-PCNL and tripling the total dilation area [18]. These  
35 findings explain why the tract dilation size is associated with hemorrhagic complications. The impact  
36 of a tract dilation on a pediatric kidney, which mean longest diameter is 9 cm in 10-year-old patients,  
37 is even more significant. However, their superiority in terms of safety and efficacy compared to  
38 conventional PCNL is still under debate.  
39  
40  
41  
42  
43  
44  
45

46 The smaller tract size may be associated with decreased SFRs and, because of poor fluid drainage,  
47 elevated intra-renal pressures for a longer OT with respect to standard PCNL, increase the risk of  
48 infective complications [19,20].  
49

50 In children with stones larger than 2 cm, Saad et al. showed that mini-PCNL has a higher SFR than  
51 RIRS (71% vs 95.5%, p=0.046), but it is nonetheless associated to higher radiation exposure, longer  
52  
53  
54  
55

1 hospital stay and more complications [21,22]. The rate of fever in the PCNL group was twice the one  
2  
3 of the RIRS group.

4 To improve the clinical outcomes related to mini-PCNL, research is currently focusing on avoiding  
5  
6 high intra-renal pressures [23]. vmPCNL system may control and limit intra-renal pressures above  
7  
8 the physiological limit of 30 mmHg, beside reducing the dissemination of stones in the pyelocaliceal  
9  
10 system during lithotripsy [12,14].

11 To the best of our knowledge, our study is the first to describe the use of a vmPCNL system in the  
12  
13 pediatric population. Our study demonstrated the feasibility of a vmPCNL approach in pediatric  
14  
15 patients. No intra-operative complications were recorded. During the post-operative period, no blood  
16  
17 transfusions were required, and 5 procedures were complicated by fever, with onset usually happened  
18  
19 on the first 24 hours.

20 Rashid et al. reported an initial SFR after Mini-PCNL for complex staghorn stones in children of  
21  
22 78%, which increased to 89% after a few ancillary procedures [24]. Their median OT was 91 min  
23  
24 (range 55–130 min). Our SFRs (81.3 and 93.8%) were comparable to the ones reported in the  
25  
26 literature. The SFR might be significantly conditioned by patients' predisposing factors to stone  
27  
28 formation (Table 1), which were present in 53.8% (7/13) of patients enrolled in our study. Moreover,  
29  
30 the stone burden was significant (median cumulative stone size = 32 mm). The vmPCNL seems a  
31  
32 sustainable procedure as total cost per procedure is slightly higher than a mini-PCNL using a reusable  
33  
34 set. Moreover, the average cost of a vmPCNL resembles the costs reported in literature for  
35  
36 percutaneous surgeries, ranging from 562.79 € to 749.39 € [25]. Our study presents several  
37  
38 limitations. To start with, the study design is associated with a low level of evidence, as it is not a  
39  
40 comparative study. The sample was relatively small. Both pre-operative stone burden and post-  
41  
42 operative status assessment were heterogeneous and not performed with the most accurate  
43  
44 radiological exams. Indeed, radiological assessment should be performed by CT imaging, as US has  
45  
46 a low sensitivity and inability to properly measure stone size [26]. This is in contrast with the pursuit  
47  
48 of limiting radiation exposure in children. Which is why we preferred to assess the SFR with US and  
49  
50 KUB x-rays limiting radiation exposure. As a result, SFR might have been overestimated. We  
51  
52 reported only the largest stone diameter instead of the entire stone volume [27]. The cumulated stone  
53  
54 size uses only one dimension, and this may limit its reliability, especially in case of complex stone  
55  
56 shape and stones > 20 mm [28,29].

57 According to our experience, the continuous aspiration was associated with a clear vision during the  
58  
59 procedure. Considering our high-risk population, the limited incidence of infectious complications in  
60  
61 our series may be associated with the low intra-renal pressures, warranted by the aspiration system.

1 Moreover, the facilitated litholapaxy and the absence of fragments scattering, guaranteed by the  
2 vmPCNL, may decrease OT and the need for disposable devices.  
3  
4

### 6 **CONCLUSIONS**

7 The use of a vmPCNL system seems to be a sustainable, safe and feasible procedure for kidney stones  
8 treatment in the pediatric population. Further multi-institutional RCTs are mandatory to test our initial  
9 hypothesis and to compare clinical outcomes of mini-PCNL using a reusable set versus vmPCNL.  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53

### 54 **REFERENCES**

55

- 1 [1] Rassweiler J, Rassweiler MC, Klein J. New technology in ureteroscopy and percutaneous  
2 nephrolithotomy. *Current Opinion in Urology* 2016;26:95–106.
- 3 [2] Fernström I, Johansson B. Percutaneous pyelolithotomy. A new extraction technique. *Scand*  
4 *J Urol Nephrol* 1976;10:257–9.
- 5 [3] Sen H, Seckiner I, Bayrak O, Dogan K, Erturhan S. A comparison of micro-PERC and  
6 retrograde intrarenal surgery results in pediatric patients with renal stones. *Journal of Pediatric*  
7 *Urology* 2017;13:619.e1-619.e5.
- 8 [4] Ishii H, Griffin S, Somani BK. Flexible ureteroscopy and lasertripsy (FURSL) for paediatric  
9 renal calculi: Results from a systematic review. *Journal of Pediatric Urology* 2014;10:1020–5.
- 10 [5] EAU Guidelines. Edn. prese. Arnhem, The Netherlands: EAU Guidelines Office; 2019.
- 11 [6] De S, Autorino R, Kim FJ, Zargar H, Laydner H, Balsamo R, et al. Percutaneous  
12 nephrolithotomy versus retrograde intrarenal surgery: A systematic review and meta-analysis.  
13 *European Urology* 2015;67:125–37.
- 14 [7] Zanetti SP, Boeri L, Gallioli A, Talso M, Montanari E. Minimally invasive PCNL - MIP.  
15 *Archivos Espanoles de Urologia* 2017;70:226–34.
- 16 [8] Li LY, Gao X, Yang M, Li JF, Zhang H Bin, Xu WF, et al. Does a Smaller Tract in  
17 Percutaneous Nephrolithotomy Contribute to Less Invasiveness? A Prospective Comparative Study.  
18 *Urology* 2010;75:56–61.
- 19 [9] Zhu W, Liu Y, Liu L, Lei M, Yuan J, Wan SP, et al. Minimally invasive versus standard  
20 percutaneous nephrolithotomy: a meta-analysis. *Urolithiasis* 2015;43:563–70.
- 21 [10] Tokas T, Herrmann TRW, Skolarikos A, Nagele U. Pressure matters: intrarenal pressures  
22 during normal and pathological conditions, and impact of increased values to renal physiology.  
23 *World Journal of Urology* 2019;37:125–31.
- 24 [11] Tokas T, Skolarikos A, Herrmann TRW, Nagele U. Pressure matters 2: intrarenal pressure  
25 ranges during upper-tract endourological procedures. *World Journal of Urology* 2019;37:133–42.
- 26 [12] Zeng G, Wan S, Zhao Z, Zhu J, Fuerxun A, Song C, et al. Super-mini percutaneous  
27 nephrolithotomy (SMP): A new concept in technique and instrumentation. *BJU International*  
28 2016;117:655–61.
- 29 [13] Clavien PA, Barkun J, de Oliveira ML, Vauthey JN, Dindo D, Schulick RD, et al. The  
30 Clavien-Dindo Classification of Surgical Complications. *Annals of Surgery* 2009;250:187–96.
- 31 [14] Zanetti SP, Lievore E, Fontana M, Turetti M, Gallioli A, Longo F, et al. Vacuum-assisted  
32 mini-percutaneous nephrolithotomy: a new perspective in fragments clearance and intrarenal  
33 pressure control. *World J Urol* 2020.
- 34 [15] Bujons A, Millán F, Centeno C, Emiliani E, Sánchez Martín F, Angerri O, et al. Mini-  
35 percutaneous nephrolithotomy with high-power holmium YAG laser in pediatric patients with  
36 staghorn and complex calculi. *Journal of Pediatric Urology* 2016;12:253.e1-253.e5.
- 37 [16] Berrettini A, Boeri L, Montanari E, Mogiatti M, Acquati P, De Lorenzis E, et al. Retrograde  
38 intrarenal surgery using ureteral access sheaths is a safe and effective treatment for renal stones in  
39 children weighing <20 kg. *Journal of Pediatric Urology* 2018;14:59.e1-59.e6.
- 40 [17] Zeng G, Zhu W, Lam W. Miniaturised percutaneous nephrolithotomy: Its role in the  
41 treatment of urolithiasis and our experience. *Asian Journal of Urology* 2018;5:295–302.
- 42 [18] Emiliani E, Talso M, Baghdadi M, Traxer O. Renal parenchyma injury after percutaneous  
43 nephrolithotomy tract dilatations in pig and cadaveric kidney models. *Cent European J Urol*  
44 2017;70:69–75. <https://doi.org/10.5173/cej.2017.930>.
- 45 [19] Kaygısız O, Satar N, Gürocak S, Kefi A, İzol V, Önal B, et al. Factors predicting  
46 postoperative febrile urinary tract infection following percutaneous nephrolithotomy in prepubertal  
47 children. *Journal of Pediatric Urology* 2018;14:448.e1-448.e7.
- 48 [20] Loftus CJ, Hinck B, Makovey I, Sivalingam S, Monga M. Mini Versus Standard  
49 Percutaneous Nephrolithotomy: The Impact of Sheath Size on Intrarenal Pelvic Pressure and  
50 Infectious Complications in a Porcine Model. *Journal of Endourology* 2018;32:350–3.
- 51 [21] Saad KSM, Youssif ME, Hamdy SAIN, Fahmy A, El Din Hanno AG, El-Nahas AR.
- 52
- 53
- 54
- 55

1 Percutaneous nephrolithotomy vs retrograde intrarenal surgery for large renal stones in pediatric  
 2 patients: A randomized controlled trial. *Journal of Urology* 2015;194:1716–20.

3 [22] Lu P, Song R, Yu Y, Yang J, Qi K, Tao R, et al. Clinical efficacy of percutaneous  
 4 nephrolithotomy versus retrograde intrarenal surgery for pediatric kidney urolithiasis. *Medicine*  
 5 (United States) 2017;96.

6 [23] Walcher U, Horstmann M, Anastasiadis AG, Nagele U, Hennenlotter J, Sievert K-D, et al. A  
 7 Newly Designed Amplatz Sheath Decreases Intrapelvic Irrigation Pressure During Mini-  
 8 Percutaneous Nephrolitholapaxy: An in-Vitro Pressure-Measurement and Microscopic Study .  
 9 *Journal of Endourology* 2007;21:1113–6.

10 [24] Rashid AO, Amin SH, Al Kadum MA, Mohammed SK, Buchholz N. Mini-Percutaneous  
 11 Nephrolithotomy for Complex Staghorn Stones in Children. *Urologia Internationalis* 2019:1–4.

12 [25] Schoenthaler M, Wilhelm K, Hein S, Adams F, Schlager D, Wetterauer U, et al. Ultra-mini  
 13 PCNL versus flexible ureteroscopy: a matched analysis of treatment costs (endoscopes and  
 14 disposables) in patients with renal stones 10-20 mm. *World J Urol* 2015;33:1601–5.

15 [26] Ganesan V, De S, Greene D, Torricelli FCM, Monga M. Accuracy of ultrasonography for  
 16 renal stone detection and size determination: is it good enough for management decisions? *BJU*  
 17 *International* 2017;119:464–9.

18 [27] De Coninck V, Traxer O. The Time Has Come to Report Stone Burden in Terms of Volume  
 19 Instead of Largest Diameter. *Journal of Endourology* 2018;32:265–6.

20 [28] Ito H, Kawahara T, Terao H, Ogawa T, Yao M, Kubota Y, et al. Utility and limitation of  
 21 cumulative stone diameter in predicting urinary stone burden at flexible ureteroscopy with holmium  
 22 laser lithotripsy: a single-center experience. *PLoS ONE* 2013;8:e65060.

23 [29] Giusti G, Proietti S, Villa L, Cloutier J, Rosso M, Gadda GM, et al. Current Standard  
 24 Technique for Modern Flexible Ureteroscopy: Tips and Tricks. *Eur Urol* 2016;70:188–94.

25  
 26  
 27  
 28 **Conflicts of interest:** The Authors declare nothing to disclose.

29  
 30  
 31 **Authors' contributions:**

32 Study design: Berrettini A, Bujons A, Manzoni G, Montanari E

33 Data collection: Gallioli A, Sampogna G, Quiróz Y, Llorens E

34 Manuscript writing: Gallioli A, Sampogna G, Gnech M, De Lorenzis E

35 Manuscript editing: Bujons A, Montanari E, Palou J, Albo G

36  
 37  
 38  
 39  
 40  
 41 **Funding:** none

42  
 43 **Acknowledgements:** Carolina Bebi for language revision and Irene Fulgheri for cost analysis.  
 44  
 45  
 46  
 47  
 48  
 49  
 50  
 51  
 52  
 53  
 54  
 55



## TABLES

**Table 1.** Baseline characteristics of the population

Parameters	Values
<b>No. patients</b>	13 - 8 Milan (61.5%) - 5 Barcelona (38.5%)
<b>No. renal units</b>	16
<b>No. vmPCNLs</b>	18
<b>Sex</b>	- Males: 8 (61.5%) - Females: 5 (38.5%)
<b>Age (months) median (IQR)</b>	119 (97-160)
<b>Weight (Kg) median (IQR)</b>	29 (25-40)
<b>BMI (Kg/m<sup>2</sup>) median (IQR)</b>	17.7 (16.4-18.3)
<b>Type of stone</b>	- Staghorn: 8 (44.4%) - Multiple: 15 (83.3%)
<b>Stone side</b>	- Right: 10 (55.6%) - Left: 8 (44.4%)
<b>Cumulative stone size (mm)* median (IQR)</b>	32 (22-46)
<b>No. patients with comorbidities</b>	7 (53.8%) - Primary hyperoxaluria type 1 (7.7%) - Cystinuria: 2 (15.4%) - Bladder exstrophy: 1 (7.7%) - Distal renal tubular acidosis: 1 (7.7%) - Bilateral ureteral reimplantation according to Cohen: 1 (7.7%) - Kabuki syndrome: 1 (7.7%) - Posterior urethral valves: 1 (7.7%) - Gastroschisis: 1 (7.7%)
<b>Pre-operative condition</b>	- Ureteral DJ stent: 6 (33.3%) - Nephrostomy tube: 2 (11.1%) - Ureteral DJ stent + nephrostomy tube: 2 (11.1%)
<b>Pre-operative hemoglobin (g/dL) median (IQR)</b>	13.2 (12.1-13.7)
<b>Pre-operative creatinine (mg/dL) median (IQR)</b>	0.7 (0.5-1.1)
<b>Pre-operative sodium (mEq/dL) median (IQR)</b>	140 (138-142)
<b>Pre-operative potassium (mEq/dL) median (IQR)</b>	4.6 (4.3-4.7)
<b>Pre-operative calcium (mg/dL) median (IQR)</b>	9.8 (9.6-9.9)
<b>Pre-operative uric acid (mg/dL) median (IQR)</b>	3.9 (3.4-4.2)
<b>Positive pre-operative urine culture (%)</b>	5.6 (1/18) - Pseudomonas aeruginosa

\* Cumulative stone size was evaluated as sum of largest stones diameter

BMI = body mass index; IQR = inter-quartile range; vmPCNL = semi-closed-circuit vacuum-assisted Mini-PCNL.



**Table 2.** Intra- and post-operative data of the patients submitted to vmPCNL

Parameters	Values
<b>Operative time (min) median (IQR)</b>	128 (99-167)
<b>Tract location</b>	Upper calyx: 3 (12.5) Middle calyx: 7 (29.2) Lower calyx: 14 (58.3)
<b>Tract</b>	Single: 13 (72.2) Multiple: 5 (27.8)
<b>Intra-operative complications (%)</b>	0
<b>Exit strategy</b>	- Nephrostomy tube: 15 (83.3%) [in one case: two nephrostomy tubes] - Tubeless: 3 (16.7%) - double-J ureteral stent: 3 (16.7%) - single-J ureteral catheter: 5 (27.8%)
<b>Stone composition</b>	- Calcium oxalate monohydrate: 3 (23.1%) - Calcium oxalate monohydrate and calcium carbonate: 3 (23.1%) - Cystine: 2 (15.4%) - Phosphate-based infectious stones (e.g. struvite, carboapatite): 5 (38.5%)
<b>Fever (%)</b>	27.8 (5/18)
<b>Blood transfusion (%)</b>	0
<b>Complications according to Clavien-Dindo classification (%)</b>	
- Grade I-II	- 33.3 (6/18)
- Grade IIIa	- 5.6 (1/18)
<b>Hospital stay (days) median (IQR)</b>	3 (3-6)
<b>Post-operative hemoglobin (g/dL) median (IQR)*</b>	12.1 (11.3-13.2)
<b>Post-operative creatinine (mg/dL) median (IQR)**</b>	0.61 (0.52-0.86)
<b>Post-operative CRP (mg/L) median (IQR)**</b>	3.3 (1.8-4.8)
<b>Stone-free rate (%)</b>	81.3 (13/16)
<b>Stone-free rate after ancillary procedures (%)</b>	93.8 (15/16)

vmPCNL = semi-closed-circuit vacuum-assisted Mini-PCNL; CRP = C-reactive protein; IQR = inter-quartile range

**Table 3.** Analysis of the disposable and reusable materials cost for mini-PCNL, stratified for mini-PCNL using a reusable set (standard) and vacuum-assisted mini-PCNL (excluding endoscopes)

Materials	Quantity	Price (€)	Standard mini-PCNL (€)	Vacuum-assisted mini-PCNL (€)
Ureteral catheter	1	10.0	10.0	10.0
Hydrophilic wire	2	24.3	48.6	48.6
Basket	1	146.2	146.2	48.3
Laser fiber*	1	888.2	88.8	88.8
Nephrostomy set	1	73.2	73.2	73.2
Irrigation set**	1	136.1	78.4	78.4
Contrast	1	29.3	29.3	29.3
Lubrication	2	1.9	3.8	3.8
Gowns/gloves	5	2.5	12.7	12.7
Draping	1	62.0	62.0	62.0
Miscellaneous	/	23.6	23.6	23.6
PCNL set***	1	1475.3	134.1	/
ClearPetra	1	256.2	/	256.2
<b>Total</b>	/	/	710.7	734.8

\* Depreciation calculated on 10 procedures




\*\* Depreciation calculated on 4 procedures


\*\*\* Depreciation calculated on the number of pediatric PCNLs performed in the last 24 months

## TITLES OF FIGURES

1  
2  
3 **Figure 1.** A) The ClearPetra® system (Well Lead Medical Co., Ltd., China), is shown. A plug is put  
4 over the external access to prevent the medium from flowing out. The sheath is equipped with a lateral  
5 arm connected to the aspiration system through a 200 ml plastic bottle, which collects stone  
6 fragments. B) The pressure vent on the lateral arm is used to regulate aspiration and the red stripe on  
7 the sheath is the mark for endoscope retraction. D) Lapaxy is performed by slowly drawing back the  
8 nephroscope inside the sheath until the red stripe on the sheath, thus aspirating the fragments in the  
9 lateral arm.  
10  
11  
12  
13  
14  
15  
16  
17  
18

19 **Figure 2.** Estimation of the pressures involved in the employed system. The entire circuit was  
20 considered as closed for estimation purposes. Bernoulli's principle states the total pressure is a  
21 constant in the system and derives from the sum of static and dynamic pressures. In the example  
22 shown, we considered the 16-Fr nephrostomy sheath and 12-Fr nephroscope, evaluating the aspiration  
23 pressure in  $p = -13.013Pa = -133 \text{ cmH}_2\text{O}$ . To estimate the pressure with a 9.5-Fr ureteroscope and a  
24 14-Fr nephrostomy sheath, the values of  $r_1$  and  $r_2$  were modified accordingly, obtaining a final  
25 aspiration pressure  $p = -14.00Pa = -143 \text{ cmH}_2\text{O}$ .  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55





1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55

## Supplementary Digital Material

Download supplementary material file: [Minerva Urol Nefrol-3951\\_Supplementary Digital Material1\\_V1\\_2020-05-15.docx](#)

PEER REVIEW COPY  
Minerva Urologica e Nefrologica

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55